Deal Details

Coherus Completes $230 Million Privately Negotiated Redemption of Debt Due 2026

Healthcare

Coherus privately negotiated redemption of debt due 2026

Summary

Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS) has completed a privately negotiated redemption of convertible debt due 2026. The redemption was funded with proceeds from the sale of its UDENYCA franchise to Intas Pharmaceuticals Limited.

Baird served as co-advisor to Coherus on this transaction.

About

Coherus is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), growing revenues and a promising pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck and other cancers. The Company’s strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its partners’, driving sales multiples and synergies from proprietary combinations.

Coherus’ immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in multiple Phase 1/2 and Phase 2 studies in patients with advanced solid tumors including in non-small cell lung cancer and in hepatocellular carcinoma. CHS-114 is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1 studies in patients with advanced solid tumors, including head and neck squamous cell carcinoma and gastric cancer.

Healthcare

Coherus privately negotiated redemption of debt due 2026